Resources

Resources

Understanding the history of Research Security

This infographic provides a short overview of the history of Research Security and how Dimensions helps you navigate the landscape.

Navigating the AI landscape: understanding trends, jargon, and data readiness

AI’s importance is rapidly growing, especially with Generative AI, which is expected to add trillions to global output by 2030. This white paper looks at trends in AI research outputs, and reveals a surge in AI-related research, especially after 2020, coinciding with the rise of Generative AI and large language…

Oxford University Press: Enhancing Data Analysis

Learn how OUP uses Dimensions to analyze journal health, track trends, and inform strategy.

Report: Transparency and Integrity Risks in China’s Research Ecosystem

“Transparency and Integrity Risks in China’s Research Ecosystem: A Primer and Call to Action” , a comprehensive analysis, which utilized data from Dimensions , is co-authored by Jeff Stoff, Founder and President of the Center for Research Integrity, Dr. Leslie McIntosh, Vice President of Research Integrity at Digital Science, and…

Easier, quicker, and effective: How one automotive company supercharged R&D with Dimensions

Learn how a commercial team uses Dimensions to drive business growth with prospecting and market mapping.

A new approach to prospecting and market mapping

Learn how a commercial team uses Dimensions to drive business growth with prospecting and market mapping.

White Paper: Dimensions Research Integrity

Trust markers – the explicit statements on a paper such as funding, data availability, conflict of interest, author contributions, and ethical approval – represent a contract between authors and readers that proper research practices have been observed. Trust markers highlight research a level of transparency within a publication and reduce…

White Paper: Hot topics in Pharma

The pressure to innovate is especially high, with patents for important, best selling biologics drugs on the way to expiry. As blockbuster brands lose exclusivity, makers of originator drugs are vying with companies producing new, cheaper biosimilar alternatives to retain shares of the market. Efforts to replenish R&D pipelines and…

Inform open access publishing strategies and evaluate transformative agreements

How to find and analyze data surrounding authorship and funding in topical areas by country, geography, institution, and funder.
1
2
3
13

Sign up for our newsletter